Xeris Biopharma (XERS) Is Down 9.3% After XP-8121 Patent Milestone Is Announced – Has The Bull Case Changed? - Yahoo Finance: Xeris Biopharma (XERS) Is Down 9.3% After XP-8121 Patent Milestone Is Announced – Has The Bull Case Changed? Yahoo Finance
Xeris Biopharma (XERS) Is Down 9.3% After XP-8121 Patent Milestone Is Announced – Has The Bull Case Changed? - Yahoo Finance
Xeris Biopharma (XERS) Is Down 9.3% After XP-8121 Patent Milestone Is Announced – Has The Bull Case Changed? Yahoo Finance
news.google.com
December 6, 2025 at 9:29 AM
Xeris Biopharma (XERS) Is Down 9.3% After XP-8121 Patent Milestone Is Announced – Has The Bull Case Changed? - Yahoo Finance: Xeris Biopharma (XERS) Is Down 9.3% After XP-8121 Patent Milestone Is Announced – Has The Bull Case Changed? Yahoo Finance
Xeris Biopharma (XERS) Is Down 9.3% After XP-8121 Patent Milestone Is Announced – Has The Bull Case Changed? - Yahoo Finance UK: Xeris Biopharma (XERS) Is Down 9.3% After XP-8121 Patent Milestone Is Announced – Has The Bull Case Changed? Yahoo Finance UK
Xeris Biopharma (XERS) Is Down 9.3% After XP-8121 Patent Milestone Is Announced – Has The Bull Case Changed? - Yahoo Finance UK
Xeris Biopharma (XERS) Is Down 9.3% After XP-8121 Patent Milestone Is Announced – Has The Bull Case Changed? Yahoo Finance UK
news.google.com
December 6, 2025 at 9:24 AM
Xeris Biopharma (XERS) Is Down 9.3% After XP-8121 Patent Milestone Is Announced – Has The Bull Case Changed? - Yahoo Finance UK: Xeris Biopharma (XERS) Is Down 9.3% After XP-8121 Patent Milestone Is Announced – Has The Bull Case Changed? Yahoo Finance UK
Xeris Biopharma Receives Notice of Allowance for XP-8121 Patent - MarketScreener: Xeris Biopharma Receives Notice of Allowance for XP-8121 Patent MarketScreener
Xeris Biopharma Receives Notice of Allowance for XP-8121 Patent - MarketScreener
Xeris Biopharma Receives Notice of Allowance for XP-8121 Patent MarketScreener
news.google.com
December 1, 2025 at 1:14 PM
Xeris Biopharma Receives Notice of Allowance for XP-8121 Patent - MarketScreener: Xeris Biopharma Receives Notice of Allowance for XP-8121 Patent MarketScreener
Xeris Biopharma Holdings, Inc. Receives Notice of Allowance for XP-8121 Patent - TradingView: Xeris Biopharma Holdings, Inc. Receives Notice of Allowance for XP-8121 Patent TradingView
Xeris Biopharma Holdings, Inc. Receives Notice of Allowance for XP-8121 Patent - TradingView
Xeris Biopharma Holdings, Inc. Receives Notice of Allowance for XP-8121 Patent TradingView
news.google.com
December 1, 2025 at 1:05 PM
Xeris Biopharma Holdings, Inc. Receives Notice of Allowance for XP-8121 Patent - TradingView: Xeris Biopharma Holdings, Inc. Receives Notice of Allowance for XP-8121 Patent TradingView
Xeris Biopharma (XERS) Advances with New Patent Approval - GuruFocus: Xeris Biopharma (XERS) Advances with New Patent Approval GuruFocus
Xeris Biopharma (XERS) Advances with New Patent Approval - GuruFocus
Xeris Biopharma (XERS) Advances with New Patent Approval GuruFocus
news.google.com
December 1, 2025 at 12:42 PM
Xeris Biopharma (XERS) Advances with New Patent Approval - GuruFocus: Xeris Biopharma (XERS) Advances with New Patent Approval GuruFocus
Xeris Pharmaceuticals Secures Patent Allowance for XP-8121 - TipRanks: Xeris Pharmaceuticals Secures Patent Allowance for XP-8121 TipRanks
Xeris Pharmaceuticals Secures Patent Allowance for XP-8121 - TipRanks
Xeris Pharmaceuticals Secures Patent Allowance for XP-8121 TipRanks
news.google.com
December 1, 2025 at 12:42 PM
Xeris Pharmaceuticals Secures Patent Allowance for XP-8121 - TipRanks: Xeris Pharmaceuticals Secures Patent Allowance for XP-8121 TipRanks
Xeris Biopharma receives patent allowance for hypothyroidism drug By Investing.com - Investing.com South Africa: Xeris Biopharma receives patent allowance for hypothyroidism drug By Investing.com Investing.com South Africa
Xeris Biopharma receives patent allowance for hypothyroidism drug By Investing.com - Investing.com South Africa
Xeris Biopharma receives patent allowance for hypothyroidism drug By Investing.com Investing.com South Africa
news.google.com
December 1, 2025 at 12:33 PM
Xeris Biopharma receives patent allowance for hypothyroidism drug By Investing.com - Investing.com South Africa: Xeris Biopharma receives patent allowance for hypothyroidism drug By Investing.com Investing.com South Africa
Xeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent Application - Markets Financial Content: Xeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent Application Markets Financial Content
Xeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent Application - Markets Financial Content
Xeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent Application Markets Financial Content
news.google.com
December 1, 2025 at 12:24 PM
Xeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent Application - Markets Financial Content: Xeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent Application Markets Financial Content
Xeris Biopharma receives patent allowance for hypothyroidism drug - Investing.com: Xeris Biopharma receives patent allowance for hypothyroidism drug Investing.com
Xeris Biopharma receives patent allowance for hypothyroidism drug - Investing.com
Xeris Biopharma receives patent allowance for hypothyroidism drug Investing.com
news.google.com
December 1, 2025 at 12:10 PM
Xeris Biopharma receives patent allowance for hypothyroidism drug - Investing.com: Xeris Biopharma receives patent allowance for hypothyroidism drug Investing.com
Xeris Biopharma (Nasdaq: XERS) receives USPTO Notice of Allowance for XP-8121 - Stock Titan: Xeris Biopharma (Nasdaq: XERS) receives USPTO Notice of Allowance for XP-8121 Stock Titan
Xeris Biopharma (Nasdaq: XERS) receives USPTO Notice of Allowance for XP-8121 - Stock Titan
Xeris Biopharma (Nasdaq: XERS) receives USPTO Notice of Allowance for XP-8121 Stock Titan
news.google.com
December 1, 2025 at 12:06 PM
Xeris Biopharma (Nasdaq: XERS) receives USPTO Notice of Allowance for XP-8121 - Stock Titan: Xeris Biopharma (Nasdaq: XERS) receives USPTO Notice of Allowance for XP-8121 Stock Titan
#XERS Xeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent Application
https://www.stocktitan.net/news/XERS/xeris-announces-notice-of-allowance-from-u-s-patent-and-trademark-9z49t32ukyiv.html
https://www.stocktitan.net/news/XERS/xeris-announces-notice-of-allowance-from-u-s-patent-and-trademark-9z49t32ukyiv.html
www.stocktitan.net
December 1, 2025 at 12:00 PM
#XERS Xeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent Application
https://www.stocktitan.net/news/XERS/xeris-announces-notice-of-allowance-from-u-s-patent-and-trademark-9z49t32ukyiv.html
https://www.stocktitan.net/news/XERS/xeris-announces-notice-of-allowance-from-u-s-patent-and-trademark-9z49t32ukyiv.html
Leerink Partnrs Forecasts Xeris Biopharma FY2025 Earnings Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Free Report) – Equities researchers at Leerink Partnrs increased their FY2025 earnings pe...
#Analyst #Articles #- #Estimates #Companies
Origin | Interest | Match
#Analyst #Articles #- #Estimates #Companies
Origin | Interest | Match
November 17, 2025 at 6:23 AM
Leerink Partnrs Forecasts Xeris Biopharma FY2025 Earnings Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Free Report) – Equities researchers at Leerink Partnrs increased their FY2025 earnings pe...
#Analyst #Articles #- #Estimates #Companies
Origin | Interest | Match
#Analyst #Articles #- #Estimates #Companies
Origin | Interest | Match
Xeris Biopharma (XERS): Valuation Insights After New Recorlev Patent, Profit Boost, and 2025 Outlook Upgrade - simplywall.st: Xeris Biopharma (XERS): Valuation Insights After New Recorlev Patent, Profit Boost, and 2025 Outlook Upgrade simplywall.st
Xeris Biopharma (XERS): Valuation Insights After New Recorlev Patent, Profit Boost, and 2025 Outlook Upgrade - simplywall.st
Xeris Biopharma (XERS): Valuation Insights After New Recorlev Patent, Profit Boost, and 2025 Outlook Upgrade simplywall.st
news.google.com
November 16, 2025 at 7:31 PM
Xeris Biopharma (XERS): Valuation Insights After New Recorlev Patent, Profit Boost, and 2025 Outlook Upgrade - simplywall.st: Xeris Biopharma (XERS): Valuation Insights After New Recorlev Patent, Profit Boost, and 2025 Outlook Upgrade simplywall.st
Xeris Biopharma Holdings ($XERS) reported EPS of 0.0 missing estimate of 0.01 for Q3 2025. Revenue 74.38 Million Vs 74.255002 Million expected.
https://fundspec.io
Chat with FundSpec AI to analyze your stocks and access financial data on the FundSpec App available on the AppStore or PlayStore!
https://fundspec.io
Chat with FundSpec AI to analyze your stocks and access financial data on the FundSpec App available on the AppStore or PlayStore!
November 6, 2025 at 12:08 PM
Xeris Biopharma Holdings ($XERS) reported EPS of 0.0 missing estimate of 0.01 for Q3 2025. Revenue 74.38 Million Vs 74.255002 Million expected.
https://fundspec.io
Chat with FundSpec AI to analyze your stocks and access financial data on the FundSpec App available on the AppStore or PlayStore!
https://fundspec.io
Chat with FundSpec AI to analyze your stocks and access financial data on the FundSpec App available on the AppStore or PlayStore!
#XERS Xeris Biopharma Posts Record Financial Results for the Third Quarter 2025
https://www.stocktitan.net/news/XERS/xeris-biopharma-posts-record-financial-results-for-the-third-quarter-08vu2cts3soh.html
https://www.stocktitan.net/news/XERS/xeris-biopharma-posts-record-financial-results-for-the-third-quarter-08vu2cts3soh.html
www.stocktitan.net
November 6, 2025 at 12:00 PM
#XERS Xeris Biopharma Posts Record Financial Results for the Third Quarter 2025
https://www.stocktitan.net/news/XERS/xeris-biopharma-posts-record-financial-results-for-the-third-quarter-08vu2cts3soh.html
https://www.stocktitan.net/news/XERS/xeris-biopharma-posts-record-financial-results-for-the-third-quarter-08vu2cts3soh.html
Nat ruining Xeri's breakfast. What's she saying? A long string of bleeps as it's too graphic, but she had a good night last night.
October 21, 2025 at 9:11 PM
Nat ruining Xeri's breakfast. What's she saying? A long string of bleeps as it's too graphic, but she had a good night last night.
Feliz fursuit friday xeris 🐺💛
September 26, 2025 at 8:34 PM
Feliz fursuit friday xeris 🐺💛
Xeris Announces Orange Book Listing of U.S. Patent for Recorlev® - Yahoo Finance: Xeris Announces Orange Book Listing of U.S. Patent for Recorlev® Yahoo Finance
Xeris Announces Orange Book Listing of U.S. Patent for Recorlev® - Yahoo Finance
Xeris Announces Orange Book Listing of U.S. Patent for Recorlev® Yahoo Finance
news.google.com
August 30, 2025 at 9:32 AM
Xeris Announces Orange Book Listing of U.S. Patent for Recorlev® - Yahoo Finance: Xeris Announces Orange Book Listing of U.S. Patent for Recorlev® Yahoo Finance
I should really try to be more active on social media, especially since suit-Xeris is a thing now.
Prepare for all the woof pictures 🐺!
Prepare for all the woof pictures 🐺!
August 28, 2025 at 5:52 PM
I should really try to be more active on social media, especially since suit-Xeris is a thing now.
Prepare for all the woof pictures 🐺!
Prepare for all the woof pictures 🐺!
Xeris Announces Orange Book Listing of U.S. Patent for Recorlev® - FinancialContent: Xeris Announces Orange Book Listing of U.S. Patent for Recorlev® FinancialContent
Xeris Announces Orange Book Listing of U.S. Patent for Recorlev® - FinancialContent
Xeris Announces Orange Book Listing of U.S. Patent for Recorlev® FinancialContent
news.google.com
August 25, 2025 at 2:19 PM
Xeris Announces Orange Book Listing of U.S. Patent for Recorlev® - FinancialContent: Xeris Announces Orange Book Listing of U.S. Patent for Recorlev® FinancialContent
Xeris Biopharma receives new patent for Recorlev extending to 2040 - Investing.com: Xeris Biopharma receives new patent for Recorlev extending to 2040 Investing.com
Xeris Biopharma receives new patent for Recorlev extending to 2040 - Investing.com
Xeris Biopharma receives new patent for Recorlev extending to 2040 Investing.com
news.google.com
August 25, 2025 at 11:10 AM
Xeris Biopharma receives new patent for Recorlev extending to 2040 - Investing.com: Xeris Biopharma receives new patent for Recorlev extending to 2040 Investing.com
Patent Protection Until 2040: Xeris Adds Critical IP Shield for Rare Disease Drug Recorlev in FDA Orange Book - Stock Titan: Patent Protection Until 2040: Xeris Adds Critical IP Shield for Rare Disease Drug Recorlev in FDA Orange Book Stock Titan
Patent Protection Until 2040: Xeris Adds Critical IP Shield for Rare Disease Drug Recorlev in FDA Orange Book - Stock Titan
Patent Protection Until 2040: Xeris Adds Critical IP Shield for Rare Disease Drug Recorlev in FDA Orange Book Stock Titan
news.google.com
August 25, 2025 at 11:05 AM
Patent Protection Until 2040: Xeris Adds Critical IP Shield for Rare Disease Drug Recorlev in FDA Orange Book - Stock Titan: Patent Protection Until 2040: Xeris Adds Critical IP Shield for Rare Disease Drug Recorlev in FDA Orange Book Stock Titan
#XERS Xeris Announces Orange Book Listing of U.S. Patent for Recorlev®
https://www.stocktitan.net/news/XERS/xeris-announces-orange-book-listing-of-u-s-patent-for-6qos08fmpdsz.html
https://www.stocktitan.net/news/XERS/xeris-announces-orange-book-listing-of-u-s-patent-for-6qos08fmpdsz.html
Patent Protection Until 2040: Xeris Adds Critical IP Shield for Rare Disease Drug Recorlev in FDA Orange Book
Xeris Biopharma's Recorlev gains new patent protection for drug-drug interaction methods. Fourth Orange Book listing extends exclusivity for Cushing's syndrome treatment through 2040.
www.stocktitan.net
August 25, 2025 at 11:00 AM
#XERS Xeris Announces Orange Book Listing of U.S. Patent for Recorlev®
https://www.stocktitan.net/news/XERS/xeris-announces-orange-book-listing-of-u-s-patent-for-6qos08fmpdsz.html
https://www.stocktitan.net/news/XERS/xeris-announces-orange-book-listing-of-u-s-patent-for-6qos08fmpdsz.html
Random Stock
Ticker: $XERS
Company: Xeris Biopharma Holdings, Inc.
Sector: Healthcare
Industry: Biotechnology
# Employees: 394
Recent Close: $7.68
52-Week High: $7.72
52-Week High Date: 08-15-2025
% Off 52-Week High: -0.52%
52-Week Low: $2.48
Ticker: $XERS
Company: Xeris Biopharma Holdings, Inc.
Sector: Healthcare
Industry: Biotechnology
# Employees: 394
Recent Close: $7.68
52-Week High: $7.72
52-Week High Date: 08-15-2025
% Off 52-Week High: -0.52%
52-Week Low: $2.48
August 18, 2025 at 5:00 PM
Random Stock
Ticker: $XERS
Company: Xeris Biopharma Holdings, Inc.
Sector: Healthcare
Industry: Biotechnology
# Employees: 394
Recent Close: $7.68
52-Week High: $7.72
52-Week High Date: 08-15-2025
% Off 52-Week High: -0.52%
52-Week Low: $2.48
Ticker: $XERS
Company: Xeris Biopharma Holdings, Inc.
Sector: Healthcare
Industry: Biotechnology
# Employees: 394
Recent Close: $7.68
52-Week High: $7.72
52-Week High Date: 08-15-2025
% Off 52-Week High: -0.52%
52-Week Low: $2.48